Androgen deprivation therapy (ADT) remains a cornerstone of the management of prostate cancer. The addition of ADT to radiotherapy improves disease-free and overall survival in the locally advanced setting and ADT forms the backbone onto which additional treatments may be added (either initially at first presentation or sequentially at disease progression). ADT is most commonly achieved with Gonadotrophin Releasing Hormone analogues (GnRHa) that act through the hypothalamic-pituitary-gonadal axis to prevent testicular production of testosterone. However, the therapeutic benefits of ADT are partially offset by its side-effects which include long-term This article is protected by copyright. All rights reserved.